Evotec (NASDAQ:EVO) Shares Cross Above 50-Day Moving Average – Time to Sell?

Evotec AG (NASDAQ:EVO) passed above its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $1.62 and traded as high as $1.82. Evotec shares last traded at $1.7750, with a volume of 273,618 shares trading hands.

More Evotec News

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Third-quarter results beat analyst expectations: Evotec reported an adjusted EBITDA loss of €1.6 million, while revenue exceeded the consensus estimate cited in reports. The company reaffirmed its 2026 outlook, and sales in its D&PD base business rose 24%. Evotec Q3 and nine-month results
• Positive Sentiment: Analyst sentiment includes a Buy rating from RBC Capital and HC Wainwright’s increase in its price target from $4 to $5, signaling potential upside in analysts’ view. RBC Capital rating HC Wainwright price target
• Neutral Sentiment: Evotec secured a manufacturing mandate from Vertex, which could support future business, though the available report does not quantify its financial contribution. Vertex manufacturing mandate
• Negative Sentiment: Nine-month revenue was lower year over year, and Evotec tempered and pushed back medium-term goals, including reducing its 2030 revenue target. That may weigh on investor confidence despite the quarterly improvement. Target changes and restructuring
• Negative Sentiment: Coverage of the Redmond expansion highlights a potential gap between added capacity and revenue generation, raising the risk that costs precede the benefits. Redmond expansion analysis

Wall Street Analysts Forecast Growth

EVO has been the subject of a number of research reports. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research note on Wednesday, July 15th. HC Wainwright upped their price target on shares of Evotec from $4.00 to $5.00 and gave the company a “buy” rating in a report on Friday. Weiss Ratings lowered Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. Finally, Berenberg Bank lowered Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $3.50.

Evotec Trading Down 4.8%

The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62. The business’s 50 day moving average is $1.62 and its two-hundred day moving average is $2.48.

Hedge Funds Weigh In On Evotec

An institutional investor recently raised its position in Evotec stock. Optiver Holding B.V. increased its position in shares of Evotec AG (NASDAQ:EVO) by 598.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 283,576 shares of the company’s stock after buying an additional 242,973 shares during the period. Optiver Holding B.V. owned 0.08% of Evotec worth $709,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 5.81% of the company’s stock.

About Evotec

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.